Skip to main content
    R

    Roivant Sciences Ltd (ROIV)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $38.61
    -0.92 (-2.33%)

    Market Cap: $28.64B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Roivant Sciences Ltd (ROIV) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Roivant Sciences reported EPS of -$0.30, above the -$0.52 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    55%(12/22)
    Avg Surprise
    +4.06%
    Streak
    1 Q

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$0.41
    Range-$0.50 - -$0.35
    3 analysts
    EPS Revisions
    0
    3
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.41+0.6%
    60d ago-$0.41+0.6%
    30d ago-$0.41+0.6%
    7d ago-$0.40-1.7%
    Current-$0.41
    Revenue Consensus
    $49.47M
    Range$37.93M - $63.49M
    3 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.30
    Range-$0.46 - -$0.10
    13 analysts
    Revenue Consensus
    $57.25M
    Range$6.60M - $101.85M
    13 analysts

    Next Report

    ROIV's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    ROIV Earnings Call

    The latest ROIV earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 22 quarters below that had an estimate, ROIV beat 12, missed 8 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $35.12M, up 2136.9% from $1.57M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.30-$0.52-$0.59 - -$0.35+42.31%BeatN/A30 up, 3 downNov 9, 2026$35.12M
    Jun 30, 2026-$0.45-$0.45-$0.47 - -$0.270.00%In lineN/A30 up, 2 downAug 6, 2026$1.44M
    Mar 31, 2026-$0.32-$0.35-$0.49 - -$0.26+8.57%BeatN/A33 up, 0 downMay 20, 2026$2.52M
    Dec 31, 2025-$0.24-$0.31-$0.45 - -$0.23+22.58%BeatN/A40 up, 2 downFeb 6, 2026$2.00M
    Sep 30, 2025-$0.28-$0.30-$0.43 - -$0.24+6.67%BeatN/A41 up, 0 downNov 10, 2025$1.57M
    Jun 30, 2025-$0.25-$0.23-$0.29 - -$0.18-8.70%MissN/A30 up, 1 downAug 11, 2025$2.17M
    Mar 31, 2025-$0.29-$0.26N/A-10.31%MissN/A32 up, 0 downMay 29, 2025$7.57M
    Dec 31, 2024-$0.20-$0.24-$0.33 - -$0.16+16.67%BeatN/A31 up, 2 downFeb 10, 2025$9.02M
    Sep 30, 2024-$0.30-$0.24-$0.34 - -$0.11-25.00%MissN/A80 up, 0 downNov 12, 2024$4.47M
    Jun 30, 2024-$0.18-$0.24-$0.32 - -$0.21+25.00%BeatN/A62 up, 0 downAug 8, 2024$7.99M
    Mar 31, 2024-$0.19-$0.30-$0.37 - -$0.23+36.67%BeatN/A61 up, 0 downMay 30, 2024N/A
    Dec 31, 2023-$0.21-$0.27-$0.38 - -$0.26+22.22%BeatN/A71 up, 1 downFeb 13, 2024$15.56M
    Sep 30, 2023-$0.29-$0.27-$0.34 - -$0.23-7.41%MissN/A71 up, 0 downNov 13, 2023$3.65M
    Jun 30, 2023-$0.28-$0.28-$0.34 - -$0.260.00%In lineN/A53 up, 0 downAug 14, 2023$21.62M
    Mar 31, 2023-$0.20-$0.36-$0.44 - -$0.30+44.44%BeatN/A80 up, 1 downJun 28, 2023N/A
    Dec 31, 2022-$0.42-$0.32-$0.50 - -$0.29-31.25%MissN/A70 up, 1 downFeb 13, 2023$17.05M
    Sep 30, 2022-$0.32-$0.34-$0.59 - -$0.29+5.88%BeatN/A70 up, 0 downNov 14, 2022$12.53M
    Jun 30, 2022-$0.30-$0.28N/A-7.14%MissN/AN/A3 up, 0 downAug 15, 2022$4.32M
    Mar 31, 2022-$0.27-$0.32-$0.40 - -$0.23+15.63%Beat-173.0%70 up, 0 downJun 28, 2022$9.22M
    Dec 31, 2021-$0.41-$0.24-$0.27 - -$0.21-70.83%MissN/A50 up, 0 downFeb 14, 2022$24.34M
    Sep 30, 2021-$0.32-$0.36-$0.74 - $0.47+11.11%BeatN/A30 up, 0 downNov 15, 2021$13.99M
    Jun 30, 2021-$0.28-$0.26N/A-7.69%MissN/AN/AN/AAug 10, 2021$7.74M
    Mar 31, 2021$0.37N/AN/AN/AN/AN/AN/AN/AMay 20, 2021$15.15M
    Dec 31, 2020-$0.01N/AN/AN/AN/AN/AN/AN/AMar 22, 2021$5.75M
    Sep 30, 2020Not reportedN/AN/AN/ANot reportedN/AN/AN/ANov 19, 2020$1.32M
    Mar 31, 2020-$0.02N/AN/AN/AN/AN/AN/AN/AJun 30, 2020N/A
    Dec 31, 2019-$0.25N/AN/AN/AN/AN/AN/AN/AMar 31, 2020N/A
    Last 27 quarters

    Annual EPS

    EPS for the fiscal year ended Mar 31, 2026 was -$1.09, after -$0.97 the year before. It was -$0.27 for the year ended Mar 31, 2020, the oldest of the 7 fiscal years shown.

    Fiscal year endedEPSChange
    Mar 31, 2026-$1.09N/A
    Mar 31, 2025-$0.97N/A
    Mar 31, 2024-$0.97N/A
    Mar 31, 2023-$1.24N/A
    Mar 31, 2022-$1.28-455.6%
    Mar 31, 2021$0.36N/A
    Mar 31, 2020-$0.27N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,300 words across 18 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,34018
    2026Q2Jun 30, 20263,92315
    2026Q1Mar 31, 20265,09614
    2025Q3Sep 30, 20257,34818
    2025Q2Jun 30, 20254,89815
    2025Q1Mar 31, 20254,98313
    2024Q3Sep 30, 20247,01010
    2024Q2Jun 30, 20245,96111

    2026Q3 Earnings Call

    Opening remarks

    Stephanie Lee Griffin Head of Investor Relations, Roivant Good morning, and thanks for joining today's call to review positive Phase II results for brepocitinib in cutaneous sarcoidosis and Roivant's financial results for the third quarter ended December 31, 2025. I'm Stephanie Lee with Roivant. Presenting today we have Matt Gline, CEO of Roivant; and Ben Zimmer, CEO of Priovant. For those dialing in via conference call, you can find the slides being presented today as well as the press release announcing these updates on our IR website at www.investor.roivant.com. We'll also be providing the current slide numbers as we present to help you follow along. I would like to remind you that we will be making certain forward-looking statements during today's presentation. We strongly encourage you to review the information that we filed with the SEC for more information regarding these forward-looking statements and related risks and uncertainties. And with that, I'll turn it over to Matt.

    Matthew Gline CEO, Roivant Thanks, Steph, and thanks, everyone, for dialing in and listening this morning. I'm going to start our presentation on Slide 5. I was sitting and talking to the team about a week ago today, looking at a draft of this morning's presentation and thinking that it was going to be a pretty boring 10-Q. We've gotten together in December for the Investor Day. We've spoken at the JPMorgan conference, and it turned out to have been a really busy week. So we have some great updates, obviously, most notably the Phase II data in brepocitinib in cutaneous sarcoidosis, which Ben is going to present on momentarily. But the truth is terrific execution and progress across the board for us this quarter. Obviously, that data is a highlight, but we also can announce today that the NDA for brepocitinib in dermatomyositis has been submitted, that the Phase IIb study for 1402 in D2T RA has fully enrolled, that the Phase II study for mosliciguat in PH-ILD has fully enrolled. And obviously, all of the updates that we're known for, including the Immunovant offering earlier that gets us now financed to greatest launch, all behind us. So just a terrific quarter and a terrific set of updates even since early January when we last got together. On Slide 6, 2026 is, again, a very busy year for us ahead. Obviously, some major events later in the year, the brepocitinib NIU Phase III, the pivotal readout in the second half. We're now going to be starting this year a Phase III study in brepocitinib for cutaneous sarcoidosis. Ben will talk a little bit more about that. It's early days in getting that going, but that will be this year.

    Frequently Asked Questions About ROIV

    Did ROIV beat earnings estimates last quarter?

    Yes. Roivant Sciences reported EPS of -$0.30 for the quarter ended Sep 30, 2026, above the -$0.52 estimate, a 42.31% surprise.

    What EPS do analysts expect from ROIV next quarter?

    The consensus EPS estimate for Roivant Sciences for the quarter ending Dec 31, 2026 is -$0.41 from 3 analysts, with estimates from -$0.50 to -$0.35.

    How often does ROIV beat earnings estimates?

    Roivant Sciences beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +9.72%.